Biologics

Global Biologics Market to Reach US$823.2 Billion by 2032

The global market for Biologics estimated at US$436.7 Billion in the year 2025, is expected to reach US$823.2 Billion by 2032, growing at a CAGR of 9.5% over the analysis period 2025-2032. Monoclonal Antibodies Drug Class, one of the segments analyzed in the report, is expected to record a 11.4% CAGR and reach US$247.0 Billion by the end of the analysis period. Growth in the Recombinant Hormones / Proteins Drug Class segment is estimated at 11.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$127.8 Billion While China is Forecast to Grow at 8.9% CAGR

The Biologics market in the U.S. is estimated at US$127.8 Billion in the year 2025. China, the world`s second largest economy, is forecast to reach a projected market size of US$143.5 Billion by the year 2032 trailing a CAGR of 8.9% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.9% and 7.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.4% CAGR.

Global Biologics Market - Key Trends & Drivers Summarized

What Is Driving the Surge in Biologics?

Biologics, or biological drugs, have emerged as a revolutionary category of therapeutics, transforming the treatment landscape for chronic and complex diseases. These large, complex molecules are derived from living cells and are engineered to target specific components of human biology, making them highly effective for conditions like cancer, autoimmune disorders, and rare genetic diseases. As more diseases are linked to genetic or molecular causes, biologics are taking center stage in the treatment of previously untreatable conditions, offering unprecedented precision and efficacy. The growing understanding of biological pathways in the human body, combined with advances in biotechnology, has made biologics a cornerstone of modern medicine.

How Are Technological Advancements Reshaping the Biologics Landscape?

Biologics are benefiting from cutting-edge advancements in biotechnology, particularly in gene editing technologies like CRISPR and developments in monoclonal antibodies and cell-based therapies. Innovations such as CAR-T therapy, which uses a patient’s immune cells to fight cancer, are pushing the boundaries of what biologics can achieve. Furthermore, advancements in biomanufacturing techniques, including continuous manufacturing and single-use technologies, are helping scale biologics production while reducing costs. These technologies are also enabling greater control over product consistency and quality, which is crucial for the commercial viability of biologics. Additionally, the rise of biosimilars is allowing more patients access to affordable biologic therapies, accelerating their market penetration globally.

What Is the Market Demand for Biologics Across Healthcare Sectors?

Biologics are widely used in various therapeutic areas, from oncology and immunology to endocrinology and infectious diseases. The increasing incidence of chronic diseases, such as diabetes, rheumatoid arthritis, and multiple sclerosis, has spurred demand for biologic therapies that offer improved outcomes over traditional small-molecule drugs. In oncology, biologics such as immunotherapies and targeted therapies have significantly improved survival rates and reduced relapse. With aging populations and the rise in autoimmune diseases, the need for long-term, effective biologic treatments is expanding. The pharmaceutical sector is also seeing a surge in R&D investment, with major companies focusing on the development of novel biologics that address unmet medical needs, particularly for rare and orphan diseases.

The growth in the biologics market is driven by several factors, including advancements in biotechnological research, the increasing prevalence of chronic and autoimmune diseases, and the growing adoption of personalized medicine. Rising demand for targeted therapies that minimize side effects while maximizing treatment efficacy is also fueling the market. Furthermore, biosimilar approvals in regions like Europe and the U.S. are expanding access to biologic therapies at lower costs, while technological innovations in biomanufacturing are streamlining production processes. The expanding application of biologics in oncology, immunology, and rare diseases, coupled with favorable regulatory environments, is expected to sustain the strong growth trajectory of the biologics market.

SCOPE OF STUDY:

The report analyzes the Biologics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Application (Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes, Other Applications); Product Type (Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy, Vaccines)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

SELECT PLAYERS -

• AbbVie, Inc.
• Amgen, Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Celgene Corporation
• Eli Lilly and Company
• GlaxoSmithKline PLC
• Merck & Co., Inc.
• Novartis AG
• Novo Nordisk A/S
• Pfizer, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more